Valuation: MacroGenics, Inc.

Market Cap 147M 131M 120M 109M 205M 13.91B 210M 1.44B 576M 7.36B 552M 541M 23.32B P/E 2026 *
-1.48x
P/E 2027 * -1.41x
Enterprise Value 147M 131M 120M 109M 205M 13.91B 210M 1.44B 576M 7.36B 552M 541M 23.32B EV / Sales 2026 *
1.36x
EV / Sales 2027 * 1.62x
Free-Float
96.51%
Yield 2026 *
-
Yield 2027 * -
1 day-0.86%
1 week-6.48%
Current month-3.75%
1 month-35.47%
3 months-40.77%
6 months-27.81%
Current year+43.48%
1 week 2.23
Extreme 2.23
2.54
1 month 1.93
Extreme 1.93
3.79
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
22.18
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 2025-08-12
Director of Finance/CFO 59 2008-04-30
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 2001-08-31
Director/Board Member 53 2025-08-12
Director/Board Member 62 2004-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Exercice

Chief Technology Officer

16,000 0.0251%
8/19/26 Sell

General Counsel

-31,105 0.0489%
8/17/26 Exercice

Chief Technology Officer

80,000 0.1259%
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%-6.48%+59.31%-56.50% 148M
+10.00%+4.50%+58.63%+71.20% 60.57B
+1.44%+5.05%+22.52%+101.03% 55.51B
+3.32%+2.31%+11.04%+75.04% 55.22B
+0.46%-5.47%+25.04%+33.77% 43.27B
+6.42%+1.18%+22.18%+105.56% 40.36B
+2.82%+5.82%+240.96%+801.17% 41.63B
-3.79%-7.50%+89.46%+77.13% 33.29B
+5.32%+5.37%+19.12%+52.98% 32.27B
+5.32%+13.43%-39.82%+342.66% 22.91B
Average +3.05%+4.72%+50.84%+160.41% 38.52B
Weighted average by Cap. +3.72%+4.84%+52.22%+169.43%

Financials

2026 *2027 *
Net sales 108M 96.41M 88.42M 80.35M 151M 10.23B 155M 1.06B 424M 5.41B 406M 397M 17.14B 90.61M 80.74M 74.04M 67.29M 126M 8.56B 129M 885M 355M 4.53B 340M 333M 14.36B
Net income -88.7M -79.04M -72.49M -65.87M -124M -8.38B -127M -866M -347M -4.44B -333M -326M -14.05B -138M -123M -113M -103M -193M -13.05B -197M -1.35B -541M -6.91B -518M -507M -21.88B
Net Debt - -
Projected Income Statement - Annual - MacroGenics, Inc.
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.
Employees
293
Date Price Change Volume
26-11-04 US$2.310 -0.86% 918,223
26-11-03 US$2.330 0.00% 409,139
26-11-02 US$2.330 -2.92% 766,121
26-10-30 US$2.400 +0.84% 1,182,982
26-10-29 US$2.380 -3.64% 744,479
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MacroGenics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.310USD
Average target price
8.000USD
Spread / Average Target
+246.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MacroGenics, Inc.
  1. Stock Market
  2. Stocks
  3. MGNX Stock